Diseño y fabricación de dispositivo táctil para el manejo y control de luces

El proyecto que se presenta en este documento, consiste en el diseño y fabricación de un dispositivo domótico, que aporta modularidad al usuario, permitiéndole configurar el dispositivo según las necesidades de su hogar, mediante un menú sencillo de configuración, en el cual el usuario establece el tipo y número de aparatos electrónicos que van a ser conectados al dispositivo. Para llevar a cabo las fases de diseño y fabricación del prototipo que servirá como ejemplo durante la presentación de este proyecto, se han utilizado distintos programas y tecnologías. Estos programas y tecnologías serán introducidos a lo largo del documento. El dispositivo presentado, estará fijado a la pared y estará conectado a los aparatos que va a controlar mediante el cableado existente en el edificio. Una vez el dispositivo está configurado, el usuario podrá realizar diferentes funciones con cada uno de los aparatos eléctricos a los que está conectado. El usuario podrá realizar estas funciones mediante la interacción con una pantalla táctil capacitiva, en la que se selecciona el aparato eléctrico sobre el que se desea actuar, así como la función a desempeñar sobre ella. Las funcionalidades que ofrece el dispositivo para los aparatos conectados, son Encender/Apagar, Subir/Bajar intensidad o programar el encendido/apagado. Los aparatos que pueden ser conectados son las luces, sobre las que se pueden realizar todas las acciones descritas, al igual que para los ventiladores, o persianas, que en este caso solo se podrá Subir/Bajar o programar la Subida/Bajada de la persiana. Todas estas funciones estarán integradas en el dispositivo en el cual se basa este proyecto. Este dispositivo es un substituto ideal para las cajas de interruptores mecánicos con varios interruptores, aportando nuevas funcionalidades y un diseño innovador, además de la entrada en modo “Ahorro de energía” cuando el dispositivo no está siendo utilizado. La aportación de este dispositivo respecto a lo existente actualmente en el mercado, será la modularidad que ofrece la fácil configuración de la que dispone, mediante la cual el usuario podrá establecer qué número y tipos de cada dispositivo van a ser conectados. Otra de las ventajas que el dispositivo aporta será el reducido precio del mismo, en comparación con los dispositivos actuales que realizan estas funciones.Ingeniería Superior de Telecomunicacione

The OTELO survey revealing a population of low-luminosity active star-forming galaxies at z ∼ 0.9

Aims. We study a sample of Hβ emission line sources at z ∼ 0.9 to identify the star-forming galaxies sample and characterise them in terms of line luminosity, stellar mass, star formation rate, and morphology. The final aim is to obtain the Hβ luminosity function of the star-forming galaxies at this redshift. Methods. We used the red tunable filter of the instrument Optical System for Imaging low Resolution Integrated Spectroscopy (OSIRIS) at Gran Telescopio de Canarias (GTC) to obtain the pseudo spectra of emission line sources in the OTELO field. From these pseudo spectra, we identified the objects with Hβ emission. As the resolution of the pseudo spectra allowed us to separate Hβ from [O iii], we were able to derive the Hβ flux without contamination from its adjacent line. Using data from the extended OTELO catalogue, we discriminated AGNs and studied the star formation rate, the stellar mass, and the morphology of the star-forming galaxies. Results. We find that our sample is located on the main sequence of star-forming galaxies. The sources are orphologically classified, mostly as disc-like galaxies (76%), and 90% of the sample are low-mass galaxies (M∗ < 10^(10) Mꙩ). The low-mass star-forming galaxies at z ∼ 0.9 that were detected by OTELO present similar properties as low-mass star-forming galaxies in the local universe, suggesting that these kinds of objects do not have a favorite epoch of formation and star formation enhancement from z ∼1 to now. Our sample of 40 Hβ star-forming galaxies include the faintest Hβ emitters detected so far. This allows us to constrain the faint end of the luminosity function for the Hβ line alone with minimum luminosity of log L = 39 erg s^(−1), which is a hundred times fainter than previous surveys. The dust-corrected OSIRIS Tunable Emission Line Object survey (OTELO) Hβ luminosity function established the faint-end slope as α = −1.36 ± 0.15. We increased the scope of the analysis to the bright end by adding ancillary data from the literature, which was not dust-corrected in this case. The obtained slope for this extended luminosity function is α = −1.43 ± 0.12

Spectrophotometric study in the near-ir of a sample of MIPS selected galaxies at Z~2

Our main objective is to determine what kind of galaxies dominate the cosmic SFR density at z~2. Our sample consists of 24 galaxies in Chandra Deep Field South, a unique field for the study of galaxy evolution (12 observed with GNIRS/GEMINI and 12 with ISAAC/VLT). We use H alpha together with the already merged X-ray, ultraviolet, optical, near and mid-infrared imaging data to obtain estimations of SFRs, metallicities, stellar and dynamical masses, AGN activity, and extinction properties. We have obtained 15 Hα detections, 4 rotation curves, and SFR relationship for 7 galaxies. The metallicities obtained for 8 galaxies of the sample are compatible with the metallicities of local galaxies

26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines

It has been demonstrated that 1,25-dihydroxyvitamin D3 (1,25D) and some of its analogues have antitumor activity. 1,25D labeled with deuterium (26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin D3, or 1,25D-d6) is commonly used as internal standard for 1,25D liquid chromatography-mass spectrometry (LC-MS) quantification. In the present study using human breast cancer cell lines, the biological activity of 1,25D-d6 administered alone and in combination with two commonly used antineoplastic agents, 5-fluorouracil and etoposide, was evaluated. Using an MTT assay, flow cytometry, and western blots, our data demonstrated that 1,25D-d6 has effects similar to the natural hormone on cell proliferation, cell cycle, and apoptosis. Furthermore, the combination of 1,25D-d6 and etoposide enhances the antitumoral effects of both compounds. Interestingly, the antitumoral effect is higher in the more aggressive MDA-MB-231 breast cancer cell line. Our data indicate that 1,25D-d6 administered alone or in combination with chemotherapy could be a good experimental method for accurately quantifying active 1,25D levels in cultures or in biological fluids, on both in vitro breast cancer cell lines and in vivo animal experimental models.Ministerio de Economía y Competividad; SAF2012-38240Ministerio de Educación e Innovación. MEI; SAF2010-15291Xunta de Galicia; CN2012/074Xunta de Galicia; INCITE08PXIB209130P

Diseño y utilización de unas prácticas de Regulación del Metabolismo como herramienta integradora de conocimientos multidisciplinares en el Grado en Biología (II)

Se pretende la creación de espacios multidisdiplinares en el Grado en Biología,con prácticas integradas de asignaturas que se cursan simultáneamente, que pudieran servir de base a propuestas de Trabajos de Fin de Grado

Lessons learned when developing a high performance attitude controlled platform to achieve microgravity for low-cost experiments

Available Attitude Control Systems are often targeted at orbital flights, and therefore manoeuvre slowly. As such, these solutions are suboptimal for sounding rocket experiments, as experiments such as those conducted on free falling units have restricted flight times. Furthermore, current attitude control systems are usually aimed at projects with extensive funding, and are therefore out of the budget range of low-cost experiments. Taking these constraints into account, the objective of project ASTER is to design and test a low-cost, fast-acting solution, to stabilise and orientate a free-falling platform, which is capable of providing microgravity conditions for experiments. The proposed design utilises three reaction wheels, controlled by a closed loop system, to stabilise the Free Falling Unit within seconds. The platform will be able to perform predefined slewing manoeuvres, which can be adapted to a wide range of applications. The free falling unit is a cube weighing around 3kg with a side length of 150 x 150 x 180 mm, with a recovery parachute system included. Designed to act as a system platform for free falling units, it will be able to accommodate future experiments, providing an easily adaptable payload bay with dimensions up to 56 x 91 x 77 mm. Furthermore, the system will be recovered after the experiment has been concluded and the results obtained will be published on an open source basis to ensure its future availability to other student and low budget research projects, thereby allowing further improvement, optimisation, and customisation. The experiment development began in September 2019 and is scheduled to fly on a sounding rocket in March 2023. Team ASTER wants to contribute to the student community by sharing the experiences and lessons learned during the project development, which is what will be focused upon in this paper and accompanying presentation

The OTELO survey: faint end of the luminosity function of [O_(II)]3727 emitters at ‹z›=1.43

Aims. In this paper, we aim to study the main properties and luminosity function (LF) of the [O II]3727 emitters detected in the OTELO survey in order to characterise the star formation processes in low-mass galaxies at z ∼ 1.43 and to constrain the faint-end of the LF. Methods. Here, we describe the selection method and analysis of the emitters obtained from narrow-band scanning techniques. In addition, we present several relevant properties of the emitters and discuss the selection biases and uncertainties in the determination of the LF and the star formation rate density (SFRD). Results. We confirmed a total of 60 sources from a preliminary list of 332 candidates as [O II]3727 emitters. Approximately 93% of the emitters have masses in the range of 10^(8) < M*/M⊙ < 10^(9). All of our emitters are classified as late-type galaxies, with a lower value of (u − v) when compared with the rest of the emitters of the OTELO survey. We find that the cosmic variance strongly affects the normalisation (ϕ*) of the LF and explains the discrepancy of our results when compared with those obtained from surveys of much larger volumes. However, we are able to determine the faint-end slope of the LF, namely, α = −1.42 ± 0.06, by sampling the LF down to ∼1 dex lower than in previous works. We present our calculation of the SFRD of our sample and compare it to the value obtained in previous studies from the literature

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Espa~nol de Trasplante Hematopoyético y Terapia Celular) Cooperative GroupsAcute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P < .001), as well as with increased nonrelapse mortality (P = .01), as compared to autoSCT. The 5-year OS was 47% (95% CI, 34-58) after autoSCT and 70% (95% CI, 59-79) after MSD alloSCT (P = .02) in this patient subgroup. In a propensity-score matched IRmol subcohort (n = 106), MSD alloSCT was associated with superior leukemia-free survival (hazard ratio [HR] 0.33, P = .004) and increased OS in patients alive 1 year after transplantation (HR 0.20, P = .004). These results indicate that, within IRcyto AML in CR1, autoSCT may be a valid option for FRmol patients, whereas MSD alloSCT should be the preferred postremission strategy in IRmol patients.Supported by a Río Hortega academic clinical fellowship (CM19/00194) from the Instituto de Salud Carlos III, Spain (E.R.A.). Additional funding has been provided by CIBERONC grants to J.P.S. (CB16/12/00480), M.M.S. (CB16/12/00369) and B.V. (CB16/12/00233)